Ebola vaccine trial launches in DRC as WHO flags accelerating death toll

The Democratic Republic of Congo is preparing to host a clinical trial of an experimental Ebola vaccine, a step that comes as the World Health Organization (WHO) warns the outbreak is moving at an unprecedented pace. Health officials say the trial will evaluate the safety and effectiveness of the vaccine among people at risk in the affected provinces, aiming to curb transmission before the disease spreads further.

The WHO’s latest figures show roughly 2,500 deaths have been recorded since the outbreak began, and alarmingly, half of those fatalities have taken place within the last 20 days. Such a rapid climb in mortality underscores the urgency of delivering medical tools to communities where the virus is circulating unchecked.

Epidemiologists note that the current surge follows a pattern of intermittent flare‑ups that have plagued the region for years. The new trial, coordinated by local health ministries and international partners, will enroll volunteers who have been exposed to the virus or who live in high‑risk zones. Participants will receive the investigational vaccine under strict monitoring, with follow‑up visits to track any adverse reactions and to assess immune response.

While the vaccine’s efficacy remains to be proven, the trial represents one of the few proactive measures available while other interventions—such as contact tracing, safe burial practices, and community education—continue. WHO officials stress that speed is essential; the concentration of deaths in a short window suggests that transmission chains are intensifying, potentially overwhelming already stretched health resources.

If successful, the vaccine could become a vital component of the broader response strategy, offering protection to frontline workers and residents alike. For now, the trial’s commencement signals a concerted effort to halt the outbreak’s momentum before the death toll climbs even higher.